Advertisement

Cancer Immunology, Immunotherapy

, Volume 57, Issue 8, pp 1115–1124 | Cite as

The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients

  • Takuya Osada
  • Gabriel Chong
  • Robert Tansik
  • Timothy Hong
  • Neil Spector
  • Rakesh Kumar
  • Herbert I. Hurwitz
  • Inderjit Dev
  • Andrew B. Nixon
  • H. Kim Lyerly
  • Timothy Clay
  • Michael A. Morse
Original Article

Abstract

Impairment of dendritic cells (DC), the most effective activators of anticancer immune responses, is one mechanism for defective antitumor immunity, but the causes of DC impairment are incompletely understood. We evaluated the association of impaired DC differentiation with angiogenesis-associated molecules D-dimer, vascular endothelial growth factor (VEGF), urokinase plasminogen activator (uPA), and plasminogen activator inhibitor (PAI-1) in peripheral blood from 41 patients with lung, breast, and colorectal carcinoma. Subsequently, we studied the effect of administration of the anti-VEGF antibody (bevacizumab) on DC maturation and function in vivo. Compared with healthy volunteers, cancer patients had a bias toward the immunoregulatory DC2, had deficits in DC maturation after overnight in vitro culture, and had a significant increase in immature myeloid cell progenitors of DC (0.50 ± 0.31% vs. 0.32 ± 0.16% of peripheral blood mononuclear cells, respectively, P = 0.011). A positive correlation was found between the percentage of DC2 and PAI-1 (R = 0.50) and between immature myeloid cells and VEGF (R = 0.52). Bevacizumab administration to cancer patients was associated with a decrease in the accumulation of immature progenitor cells (0.39 ± 0.30% vs. 0.27 ± 0.24%, P = 0.012) and induced a modest increase in the DC population in peripheral blood (0.47 ± 0.23% vs. 0.53 ± 0.30%). Moreover, anti-VEGF antibody treatment enhanced allo-stimulatory capacity of DC and T cell proliferation against recall antigens. These data suggest that DC differentiation is negatively associated with VEGF levels and may be one explanation for impaired anticancer immunity, especially in patients with advanced malignancies.

Keywords

Dendritic cell Immature myeloid cell VEGF Cancer Immunity 

Notes

Acknowledgments

We wish to thank Elizabeth Anderson and Emily Privette for their help in obtaining blood samples from the cancer patients and Sharon Peplinski for flow cytometric expertise. This project was supported by a grant from GSK and by 5 P01 CA78673.

References

  1. 1.
    Flores-Romo L (2001) In vivo maturation and migration of dendritic cells. Immunology 102:255–262PubMedCrossRefGoogle Scholar
  2. 2.
    Morse MA, Lyerly HK, Gilboa E, Nair SK (1998) Optimization of the sequence of antigen loading and CD40 ligand-induced maturation of dendritic cells. Cancer Res 58:2965–2968PubMedGoogle Scholar
  3. 3.
    Coventry BJ, Morton J (2003) CD1a-positive infiltrating-dendritic cell density and 5-year survival from human breast cancer. Br J Cancer 89:533–538PubMedCrossRefGoogle Scholar
  4. 4.
    Zeid NA, Muller HK (1993) S100 positive dendritic cells in human lung tumors associated with cell differentiation and enhanced survival. Pathology 25:338–343PubMedCrossRefGoogle Scholar
  5. 5.
    Dhodapkar MV, Steinman RM, Krasovsky J, Munz C, Bhardwaj N (2001) Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med 193:233–238PubMedCrossRefGoogle Scholar
  6. 6.
    Gabrilovich DI, Ciernik IF, Carbone DP (1996) Dendritic cells in antitumor immune responses. I. Defective antigen presentation in tumor-bearing hosts. Cell Immunol 170:101–110PubMedCrossRefGoogle Scholar
  7. 7.
    Gabrilovich DI, Corak J, Ciernik IF, Kavanaugh D, Carbone DP (1997) Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin Cancer Res 3:483–490PubMedGoogle Scholar
  8. 8.
    Ratta M, Fagnoni F, Curti A, Vescovini R, Sansoni P, Oliviero B, Fogli M, Ferri E, Della Cuna GR, Tura S, Baccarani M, Lemoli RM (2002) Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6. Blood 100:230–237PubMedCrossRefGoogle Scholar
  9. 9.
    Lathers DM, Lubbers E, Beal NM, Wright MA, Young MR (1999) Cultures derived from peripheral blood CD34+ progenitor cells of head and neck cancer patients and from cord blood are functionally different. Hum Immunol 60:1207–1215PubMedCrossRefGoogle Scholar
  10. 10.
    Almand B, Clark JI, Nikitina E, van Beynen J, English NR, Knight SC, Carbone DP, Gabrilovich DI (2001) Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol 166:678–689PubMedGoogle Scholar
  11. 11.
    Kusmartsev S, Gabrilovich DI (2002) Immature myeloid cells and cancer-associated immune suppression. Cancer Immunol Immunother 51:293–298PubMedCrossRefGoogle Scholar
  12. 12.
    Li Q, Pan PY, Gu P, Xu D, Chen SH (2004) Role of immature myeloid Gr-1+ cells in the development of antitumor immunity. Cancer Res 64:1130–1139PubMedCrossRefGoogle Scholar
  13. 13.
    Serafini P, Borrello I, Bronte V (2006) Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin Cancer Biol 16:53–65PubMedCrossRefGoogle Scholar
  14. 14.
    Veikkola T, Karkkainen M, Claesson-Welsh L, Alitalo K (2000) Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res 60:203–212PubMedGoogle Scholar
  15. 15.
    Martiny-Baron G, Marme D (1995) VEGF-mediated tumour angiogenesis: a new target for cancer therapy. Curr Opin Biotechnol 6:675–680PubMedCrossRefGoogle Scholar
  16. 16.
    Gabrilovich DI, Chen HL, Girgis KR, Cunningham HT, Meny GM, Nadaf S, Kavanaugh D, Carbone DP (1996) Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 2:1096–1103PubMedCrossRefGoogle Scholar
  17. 17.
    Dikov MM, Ohm JE, Ray N, Tchekneva EE, Burlison J, Moghanaki D, Nadaf S, Carbone DP (2005) Differential roles of vascular endothelial growth factor receptors 1 and 2 in dendritic cell differentiation. J Immunol 174:215–222PubMedGoogle Scholar
  18. 18.
    Oyama T, Ran S, Ishida T, Nadaf S, Kerr L, Carbone DP, Gabrilovich DI (1998) Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hematopoietic progenitor cells. J Immunol 160:1224–1232PubMedGoogle Scholar
  19. 19.
    Gabrilovich DI, Ishida T, Nadaf S, Ohm JE, Carbone DP (1999) Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin Cancer Res 5:2963–2970PubMedGoogle Scholar
  20. 20.
    Thomas R, Davis LS, Lipsky PE (1994) Isolation and characterization of human peripheral blood dendritic cells. J Immunol 150:821–834Google Scholar
  21. 21.
    Bertolini F, Shaked Y, Mancuso P, Kerbel RS (2006) The multifaceted circulating endothelial cell in cancer: towards marker and target identification. Nat Rev Cancer 6:835–845PubMedCrossRefGoogle Scholar
  22. 22.
    Peichev M, Naiyer AJ, Pereira D, Zhu Z, Lane WJ, Williams M, Oz MC, Hicklin DJ, Witte L, Moore MA, Rafii S (2000) Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. Blood 95:952–958PubMedGoogle Scholar
  23. 23.
    Dirix LY, Salgado R, Weytjens R, Colpaert C, Benoy I, Huget P, van Dam P, Prove A, Lemmens J, Vermeulen P (2002) Plasma fibrin D-dimer levels correlate with tumour volume, progression rate and survival in patients with metastatic breast cancer. Br J Cancer 86:389–395PubMedCrossRefGoogle Scholar
  24. 24.
    Bajou K, Masson V, Gerard RD, Schmitt PM, Albert V, Praus M, Lund LR, Frandsen TL, Brunner N, Dano K, Fusenig NE, Weidle U, Carmeliet G, Loskutoff D, Collen D, Carmeliet P, Foidart JM, Noel A (2001) The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies. J Cell Biol 152:777–784PubMedCrossRefGoogle Scholar
  25. 25.
    Baker EA, Bergin FG, Leaper DJ (2000) Plasminogen activator system, vascular endothelial growth factor, and colorectal cancer progression. Mol Pathol 53:307–312PubMedCrossRefGoogle Scholar
  26. 26.
    Blackwell K, Hurwitz H, Lieberman G, Novotny W, Snyder S, Dewhirst M, Greenberg C (2004) Circulating D-dimer levels are better predictors of overall survival and disease progression in patients with metastatic colorectal carcinoma. Cancer 101:77–82PubMedCrossRefGoogle Scholar
  27. 27.
    Mosca PJ, Hobeika AC, Colling K, Clay TM, Thomas EK, Caron D, Lyerly HK, Morse MA (2002) Multiple signals are required for maturation of human dendritic cells mobilized in vivo with Flt3 ligand. J Leukoc Biol 72:546–553PubMedGoogle Scholar
  28. 28.
    Gabrilovich D, Ishida T, Oyama T, Ran S, Kravtsov V, Nadaf S, Carbone DP (1998) Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 92:4150–4166PubMedGoogle Scholar
  29. 29.
    Ohm JE, Carbone DP (2001) VEGF as a mediator of tumor-associated immunodeficiency. Immunol Res 23:263–272PubMedCrossRefGoogle Scholar
  30. 30.
    Look MP, van Putten WL, Duffy MJ, Harbeck N, Christensen IJ, Thomssen C, Kates R, Spyratos F, Ferno M, Eppenberger-Castori S, Sweep CG, Ulm K, Peyrat JP, Martin PM, Magdelenat H, Brunner N, Duggan C, Lisboa BW, Bendahl PO, Quillien V, Daver A, Ricolleau G, Meijer-van Gelder ME, Manders P, Fiets WE, Blankenstein MA, Broet P, Romain S, Daxenbichler G, Windbichler G, Cufer T, Borstnar S, Kueng W, Beex LV, Klijn JG, O’Higgins N, Eppenberger U, Janicke F, Schmitt M, Foekens JA (2002) Pooled analysis of prognostic impact of urokinase-type plasminogen activators and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst 94:116–128PubMedGoogle Scholar
  31. 31.
    Koretz K, Moller P, Schwartz-Albiez R (1993) Plasminogen activators and plasminogen activator inhibitors in human colorectal carcinoma tissues are not expressed by the tumour cells. Eur J Cancer 29A:1184–1189PubMedGoogle Scholar
  32. 32.
    Almand B, Resser JR, Lindman B, Nadaf S, Clark JI, Kwon ED, Carbone DP, Gabrilovich DI (2000) Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res 6:1755–1766PubMedGoogle Scholar
  33. 33.
    Laxmanan S, Robertson SW, Wang E, Lau JS, Briscoe DM, Mukhopadhyay D (2005) Vascular endothelial growth factor impairs the functional ability of dendritic cells through Id pathways. Biochem Biophys Res Commun 334:193–198PubMedCrossRefGoogle Scholar
  34. 34.
    Mimura K, Kono K, Takahashi A, Kawaguchi Y, Fujii H (2007) Vascular endothelial growth factor inhibits the function of human mature dendritic cells mediated by VEGF receptor-2. Cancer Immunol Immunother 56:761–770PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • Takuya Osada
    • 1
  • Gabriel Chong
    • 1
  • Robert Tansik
    • 2
  • Timothy Hong
    • 3
  • Neil Spector
    • 1
  • Rakesh Kumar
    • 2
  • Herbert I. Hurwitz
    • 1
  • Inderjit Dev
    • 2
  • Andrew B. Nixon
    • 1
  • H. Kim Lyerly
    • 1
  • Timothy Clay
    • 1
  • Michael A. Morse
    • 1
  1. 1.Duke University Medical CenterDurhamUSA
  2. 2.GlaxoSmithKlineResearch Triangle ParkUSA
  3. 3.Hartford HospitalHartfordUSA

Personalised recommendations